Orphazyme A/S ADR (ORPHY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2021 | 06-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||
| Net Income | -99,682 | -75,490 | -97,013 |
| Depreciation Amortization | 2,881 | 2,725 | 797 |
| Accounts receivable | N/A | -1,844 | N/A |
| Other Working Capital | -148 | 10,389 | 6,551 |
| Other Operating Activity | 1,080 | 2,342 | 7,079 |
| Operating Cash Flow | $-95,869 | $-61,878 | $-82,586 |
| Cash Flows From Investing Activities | |||
| PPE Investments | 151 | N/A | -362 |
| Purchase Sale Intangibles | N/A | -131 | N/A |
| Other Investing Activity | -144 | -131 | -419 |
| Investing Cash Flow | $7 | $-131 | $-781 |
| Cash Flows From Financing Activities | |||
| Debt Repayment | N/A | -2,033 | N/A |
| Common Stock Issued | N/A | 75 | N/A |
| Other Financing Activity | -4,828 | -559 | 177,623 |
| Financing Cash Flow | $-4,828 | $-2,517 | $177,623 |
| Exchange Rate Effect | 1,304 | 861 | -1,824 |
| Beginning Cash Position | 115,654 | 117,835 | 18,934 |
| End Cash Position | 16,269 | 54,171 | 111,366 |
| Net Cash Flow | $-99,386 | $-63,664 | $92,432 |
| Free Cash Flow | |||
| Operating Cash Flow | -95,869 | -61,878 | -82,586 |
| Free Cash Flow | -95,869 | -61,878 | -82,586 |